PAVmed shifts its Veris device regulatory timeline while continuing PortIO 510(k) efforts in Q2 2026.
PAVmed announced plans to submit its Veris device for 510(k) clearance in early 2027, pushing back its previous timeline. The company remains focused on pursuing the PortIO 510(k) pathway concurrently during Q2 2026.
Management discussed the regulatory strategy during its Q2 2026 earnings call, citing operational priorities and resource allocation as key factors in the delay. The Veris device targets diagnostic applications, while PortIO addresses vascular access needs.
No immediate market reaction was disclosed in the call summary.